Objective To investigate the preventive effect of pulmonary surfactant (PS) on neonatal respiratory distress syndrome (NRDS) in preterm infants. Methods Intervention study was used.A total of 91 premature infants were selected as prevented group to receive PS,and 90 premature infants were selected as control group.All infants came from two hospitals in Guangzhou.General situation,oxygen partial pressure (PO2),carbon dioxide partial pressure (PCO2) and oxygen saturation (SPO2) index during different periods before and after treatment,NRDS outcome between the two groups were investigated. Results The demographic variables between the two groups were comparable.Before receiving PS,the PO2,PCO2 and SPO2 between the two groups were not significantly different.The values of PO2 and PCO2 after 1,6,12,24 hours of treatment in prevented group were significantly higher than those in control group.The NRDS incidence rate of prevented group (20%) was significantly lower than control group (60%).The using time of respirator and medical costs of prevented group were lower than those of control group.For the prevented group,SPO2 values after 1,6,12,24 hours of PS using were significantly higher than that before treatment,and PCO2 values were significantly lower than that before treatment.The preventive effect was better for infants with 30~34 gestational weeks than those less than 30 gestational weeks. Conclusions The preventive use of PS can effectively improve the pulmonary ventilation and oxygenation capacity,reduce the incidence of NRDS.And it can also reduce mechanical ventilation using time.The effect is better for premature infants with 30~34 gestational weeks.
Key words
pulmonary surfactant /
neonatal respiratory distress syndrome /
preterm infants
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 甘小庄,宋国维.欧洲和加拿大肺表面活性物质临床应用指南和建议[J].新生儿科杂志,2005,20(4):189-193.
[2] Goelz RB,Halliday HL.Guidelines on surfactant treatment[J].Prenat Neonat Med,2001,6(2S):84-88.
[3] 刘超,张桂欣.肺表面活性物质治疗晚期早产儿呼吸窘迫综合征疗效观察[J].新乡医学院学报,2012,29(8):623-624,627.
[4] 赵冰,潘家华.不同肺表面活性物质治疗新生儿呼吸窘迫综合征疗效比较[J].中国新生儿科杂志,2014,29 (3):158-161.
[5] 莫蔚农,王蛮蛮,孙辉,等.肺表面活性物质对不同胎龄呼吸窘迫综合征新生儿的临床研究[J].中国妇幼保健,2014,29(18):2918-2920.
[6] 袁琳,陈超.欧洲新生儿呼吸窘迫综合征防治指南-2010版[J].中华儿科杂志,2011,49(1):27-33.
[7] 肖并.新生儿呼吸窘迫综合症最新治疗方法[J].医学信息,2011,24(8):4023-4024.
[8] Horbar JD,Wright LL,Soll RF,et al.A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome[J].J Pediatr,1993,123:757-765.
[9] 王莹,马雅玲,张魏.肺表面活性物质预防早产儿RDS的临床观察[J].新生儿科杂志,2004,19(4):148-151.
[10] Stevens TP,Blennow M,Soll RF.Early surfactant administration with brief ventilation vs selective surfactant and continued mechanical ventilation for preterm infants with or at risk for RDS[J].Cochrane Database Syst Rev,2002,2:CD003063.
PDF(435 KB)
